↓ Skip to main content

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

Overview of attention for article published in Trials, August 2021
Altmetric Badge

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
11 X users

Citations

dimensions_citation
37 Dimensions

Readers on

mendeley
107 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
Published in
Trials, August 2021
DOI 10.1186/s13063-021-05538-5
Pubmed ID
Authors

Wendy Holman, Wayne Holman, Stacy McIntosh, Wendy Painter, George Painter, Jim Bush, Oren Cohen

X Demographics

X Demographics

The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 107 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 17%
Student > Master 10 9%
Other 6 6%
Student > Ph. D. Student 6 6%
Student > Bachelor 6 6%
Other 14 13%
Unknown 47 44%
Readers by discipline Count As %
Medicine and Dentistry 17 16%
Pharmacology, Toxicology and Pharmaceutical Science 10 9%
Biochemistry, Genetics and Molecular Biology 6 6%
Immunology and Microbiology 5 5%
Agricultural and Biological Sciences 4 4%
Other 17 16%
Unknown 48 45%